Pediatric growth hormone deficiency occurs when the pituitary gland fails to produce an adequate amount of growth hormone, hindering the growth of bones and other tissues. The standard treatment for growth hormone deficiency is daily injections of recombinant human growth hormone (rHGH).
The stock we are bringing to your attention today is that of Lumos Pharma Inc. (LUMO), a clinical stage biopharmaceutical company, developing a once-daily tablet for pediatric growth hormone deficiency.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.